News & Updates

In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).

The status of sentinel lymph nodes (SLN) can help predict the course of the disease in patients with clinical stage IIB/C cutaneous melanoma, suggests a study.

Delays in the treatment of melanoma may worsen overall (OM) and melanoma-specific mortality (MSM), suggest the results of a recent study.

The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.

Sigmoidoscopy screening provides a significant and sustained effect on colorectal cancer (CRC) incidence and mortality for 15 years, according to a pooled analysis of randomized trials.

As an add-on to gefitinib monotherapy, pemetrexed-based chemotherapy improves survival outcomes in nonsmall cell lung cancer (NSCLC) patients harbouring EGFR mutations, a recent study has found.

In the long-term follow-up of the KEYNOTE-604 study, the combination regimen comprising pembrolizumab and etoposide/platinum (EP*) continued to demonstrate survival benefit as first-line therapy for patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC).